证券代码：002581 证券简称：未名医药 公告编号：2023-061 山东未名生物医药股份有限公司 关于签署《山东未名生物医药产业园投资建设和资产回购 协议》暨接受关联方担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要提示： 1、本次投资建设事项，是基于公司战略发展的需要及对行业市场前景的判 断，鉴于项目实施需要经历一定的时间周期，期间的实施进展以及未来的实际 经营状况与潜在收益可能受到宏观经济政策调整、行业周期波动、市场竞争加 剧、技术更新迭代、产品需求变化以及项目运营管理等诸多不确定因素影响， 同时，本次投资建设事项尚需通过相关行政主管部门审批等一系列程序，项目 完成后还可能面临市场及技术方面的风险，存在项目建设进度或最终实现收益 不达预期的风险。 2、本次资产回购事项，如因国家或地方有关政策调整、资产权属变更等实 施条件发生变化，导致资产回购事项不能如期进行，本协议的履行可能存在延 期、变更或终止的风险。 3、因山东未名生物医药产业园一期尚未建设完毕，公司无法预计最终回购 金额，具体回购金额以年度会计师审计结果为准。 4、本次投资建设 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-063 山东未名生物医药股份有限公司 关于变更控股子公司董事、法定代表人等的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日 召开了第五届董事会第十七次会议，审议通过了《关于变更控股子公司董事、法 定代表人等的议案》。为优化公司管理结构，依据公司相关规定，公司董事会同 意将公司控股子公司天津未名生物医药有限公司（以下简称"天津未名"）董事、 法定代表人由岳家霖先生变更为张旭东先生，董事长由岳家霖先生变更为徐隽雄 先生，总经理由徐隽雄先生变更为张旭东先生。山东未名天源生物科技有限公司 （以下简称"未名天源"）将董事会制度变更为执行董事制度，由徐隽雄先生担 任执行董事。同时，公司董事会同意天津未名、未名天源根据上述变更事项修订 《公司章程》相应内容。 本次变更控股子公司董事、法定代表人等的事项无需提交公司股东大会审议， 变更内容和章程条款等的修订最终以市场监督管理部门的核准结果为准。现将有 关事项公告如下： 一、 ...

一、召开会议的基本情况 山东未名生物医药股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 证券代码：002581 证券简称：未名医药 公告编号：2023-064 （一）会议召集人：公司董事会 （2）通过互联网投票系统进行网络投票的时间：2023 年 9 月6 日 9:15-15:00。 （四）会议召开方式：现场投票与网络投票相结合的方式 公 司 将 通 过 深 圳 证 券 交 易 所 交 易 系 统 和 互 联 网 投 票 系 统 (http://wltp.cninfo.com.cn)向全体股东提供网络形式的投票平台，公司股东 可以在网络投票时间内通过上述系统行使表决权。 公司股东应选择现场投票、网络投票中的一种方式,如果同一表决权出现重 复投票表决的,以第一次有效投票表决结果为准。 （五）股权登记日：2023 年 9 月 1 日 （六）会议出席对象 （二）会议召开的合法、合规性：公司 2023 年第二次临时股东大会会议的 召集、召开符合《公司法》等法律、法规、规范性文件和《公司章程》的有关规 定。 ...

山东未名生物医药股份有限公司 独立董事关于第五届董事会第十七次会议相关议案 的独立意见 根据《关于在上市公司建立独立董事制度的指导意见》、深圳证券交易所《上 市公司规范运作指引》及山东未名生物医药股份有限公司（以下简称"公司"） 《独立董事工作制度》等相关法律法规、规章制度的有关规定，我们作为公司的 独立董事，现就公司第五届董事会第十七次会议审议的议案内容进行了认真审议， 并发表如下独立意见： 我们认为本次聘任副总经理的提名、审议、表决程序符合有关法律法规和公 司《章程》的规定，根据 WENYU ZHANG（张文宇）先生的个人简历、工作经历等 情况，其任职资格、教育背景、专业能力能够胜任所聘岗位职责的要求；未发现 其存在《公司法》中规定的不得担任公司高级管理人员的情况，以及被中国证监 会确定为市场禁入者之现象，不存在被深圳证券交易所公开认定不适合担任上市 公司高级管理人员的情况，也未曾受到过中国证监会和深圳证券交易所的任何处 罚和惩戒。同意聘任 WENYU ZHANG（张文宇）先生为公司副总经理。 1、关于聘任副总经理的独立意见 （此页无正文，为山东未名生物医药股份有限公司独立董事关于第五届董事会第 十七次会 ...

山东未名生物医药股份有限公司独立董事 关于公司第五届董事会第十七次会议相关议案的事前认可意见 综上，我们同意公司就该事项接受关联方担保，并同意将《关于签署<山东 未名生物医药产业园投资建设和资产回购协议>暨接受关联方担保的议案》提交 公司第五届董事会第十七次会议审议。 二、关于拟续聘 2023 年度会计师事务所的事前认可意见 我们对续聘 2023 年度会计师事务所表示认可。经核查，深圳广深会计师事 务所具有证券、期货相关业务执业资格，具备为上市公司提供财务报告审计和内 部控制审计服务的经验和能力，能够满足公司财务报告审计和内部控制审计工作 要求。本次拟续聘会计师事务所事项是基于公司业务发展需要，不存在损害公司 及其他股东利益、尤其是中小股东利益。 因此，我们一致同意将该议案提交第五届董事会第十七次会议审议。 （以下无正文） 我们作为山东未名生物医药股份有限公司（以下简称"公司"）的独立董事， 按照中国证监会《关于在上市公司建立独立董事制度的指导意见》、《深圳证券交 易所上市公司规范运作指引》的要求和《公司章程》、《独立董事工作制度》所赋 予的职责，对公司第五届董事会第十七次会议审议的相关议案进行了认真的事前 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-062 山东未名生物医药股份有限公司 关于续聘 2023 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、山东未名生物医药股份有限公司(以下简称"公司")2022 年度财务审计 报告的审计意见类型为带强调事项段保留意见。 2、本次拟续聘的会计师事务所名称为深圳广深会计师事务所（普通合伙） （以下简称"深圳广深会计师事务所"），不涉及变更会计师事务所的情形。 3、公司审计委员会、独立董事、董事会、监事会对本次拟续聘会计师事务 所事项无异议。本事项尚需提交公司股东大会审议。 公司于 2023 年 8 月 14 日召开第五届董事会第十七次会议、第五届监事会第 十一次会议，审议通过《关于续聘 2023 年度会计师事务所的议案》，同意拟续 聘深圳广深会计师事务所为公司 2023 年度审计机构，负责公司 2023 年度财务报 表和内部控制审计工作。本议案尚需提交公司股东大会审议。现将有关事项公告 如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 ...

Corporate Structure and Governance - The company established a wholly-owned subsidiary, Tianjin Weiming Biomedical Co., Ltd., to align with its strategic development needs, completing the transfer of 60.57% equity from Xiamen Weiming[1]. - The company directly holds 26.91% equity in Beijing Kexing Biological Products Co., Ltd. after the internal equity transfer from its wholly-owned subsidiary[2]. - The company ensures independent operations from its controlling shareholder, maintaining complete separation in business, personnel, assets, organization, and finance[23]. - The board of directors and supervisory board operate independently, adhering to relevant laws and regulations, ensuring effective governance[24][25]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, enhancing accountability[34]. - The company has a dedicated investor relations management system, ensuring timely and accurate information disclosure to all shareholders[28]. - The company has no related party transactions or competition with its controlling shareholder, as confirmed by a commitment letter from the shareholder[41]. - The company maintains an independent financial management system, with a dedicated finance team and separate bank accounts[43]. - The company has implemented a comprehensive internal governance structure, with various regulations updated as of November 2022[36][40]. - The company emphasizes the protection of stakeholders' rights, promoting a balanced approach to social, shareholder, and employee interests[35]. - The company has a clear organizational structure that operates independently from its controlling shareholder, ensuring no interference in business operations[43]. - The board of directors has undergone changes, with several members resigning due to term expiration[72]. - The company has received a qualified audit opinion for its 2022 financial statements, indicating areas requiring attention[32]. - The company has detailed major risks in the report, including policy risk, R&D risk, safety and environmental risk, and market competition risk[47]. - The company has implemented new strategies for stability and growth, as discussed in board meetings, highlighting a proactive approach to market challenges[158]. - The company has maintained a high attendance rate at board meetings, with key directors participating in all sessions, ensuring strong oversight[164]. Financial Performance - The company reported a total revenue of 286.53 million in the fiscal year 2022[66]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in 2021[96]. - The net profit attributable to shareholders for 2022 was RMB 150 million, a decrease of 10% from RMB 167 million in 2021[96]. - The company's operating revenue for 2022 was ¥357,080,537.01, a decrease of 11.33% compared to ¥402,713,045.66 in 2021[109]. - The net profit attributable to shareholders for 2022 was -¥14,689,829.85, representing a decline of 105.42% from ¥271,001,671.69 in 2021[109]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥8,497,675.71, down 103.33% from ¥255,223,170.55 in the previous year[109]. - The net cash flow from operating activities was -¥54,485,087.46, a decrease of 18.41% compared to -¥46,015,293.51 in 2021[109]. - The basic and diluted earnings per share for 2022 were -¥0.0223, a drop of 105.43% from ¥0.4108 in 2021[109]. - The weighted average return on net assets was -0.62% at the end of 2022, compared to 12.03% at the end of 2021[109]. - The total assets of the company as of December 31, 2022, were RMB 3 billion, reflecting a 5% increase from RMB 2.86 billion in 2021[96]. - The total assets at the end of 2022 were ¥2,857,915,829.17, an increase of 3.69% from ¥2,756,079,609.10 at the end of 2021[109]. - The net assets attributable to shareholders at the end of 2022 were ¥2,373,520,735.73, a decrease of 0.62% from ¥2,388,210,565.58 at the end of 2021[109]. - The operating revenue after deducting unrelated income was ¥356,182,827.24 in 2022, compared to ¥397,438,686.73 in 2021[109]. - The company reported a significant decline in both revenue and profit metrics, indicating challenges in its operational performance for the year[109]. Strategic Development and R&D - In 2023, the company aims to enhance its internal management, R&D innovation, production, and marketing capabilities to drive high-quality development[5]. - The company plans to optimize its product pipeline and advance innovative drug projects through clinical trials in 2023[6]. - The company will strengthen its production management system to ensure stable operations and enhance cost-reduction measures through technological advancements[6]. - The company intends to improve brand strength and market coverage by developing flexible product policies and innovative marketing strategies[7]. - The company acknowledges the high risks associated with new drug development, including long cycles and potential market changes affecting profitability[11]. - The company will actively seek financing channels and industry resources to support its drug development and production expansion projects[12]. - The company is committed to enhancing its product offerings and technological advancements in the upcoming fiscal year[69]. - The company aims to expand its market presence and explore potential mergers and acquisitions[69]. - The company plans to expand its market presence by increasing its investment in R&D by 20% in 2023, focusing on new biopharmaceutical products[96]. - The company is actively engaging in research and development for new products[69]. - The company has established a strategic partnership with a leading technology firm to enhance its biomanufacturing capabilities[96]. - The company is focusing on expanding its market presence and developing new products in the biopharmaceutical sector[116]. - The company is committed to expanding its market presence and enhancing its product offerings through continuous research and development efforts[152]. - The company is accelerating the research and development of second-generation nerve growth factor products to strengthen its competitive edge in the market[182]. Market and Industry Trends - The biopharmaceutical industry is expected to experience high growth due to rapid economic development and increasing health awareness in China[116]. - The biopharmaceutical industry in China is expected to exceed 4 trillion yuan in market size by 2022, driven by increasing demand due to economic development and an aging population[141]. - R&D expenditure in China's pharmaceutical manufacturing industry grew from 48.847 billion yuan in 2016 to 94.244 billion yuan in 2021, with a compound annual growth rate of 14.05%[142]. - The company operates in five major biopharmaceutical segments, including interferon, nerve growth factor, CRO/CDMO, vaccines, and pharmaceutical intermediates, ensuring stable operations across all segments[146]. - The company has a diverse vaccine portfolio including COVID-19 inactivated vaccine, EV71 inactivated vaccine, and the first hepatitis A inactivated vaccine prequalified by WHO[152]. - The company’s vaccine products are positioned to meet both domestic and international health needs, showcasing its competitive edge in the biopharmaceutical sector[152]. Human Resources and Management Changes - The company experienced a significant leadership turnover, with multiple executives resigning, including the general manager and financial director[71]. - The company has seen a significant turnover in its executive team, with multiple resignations and appointments throughout 2022[79]. - The management team includes experienced professionals with backgrounds in finance and engineering, enhancing the company's strategic capabilities[119][120]. - The company has a total of 666 employees, with 34 holding a master's degree or above, and 307 with a bachelor's degree[191]. - The company has established a performance evaluation and compensation management system for its directors and senior management, ensuring transparency and alignment with company performance[133]. Compliance and Regulatory Environment - The company has faced regulatory scrutiny in the past, with warnings issued by the China Securities Regulatory Commission for information disclosure violations[129]. - The company is committed to maintaining compliance with relevant laws and regulations to ensure sustainable growth and investor confidence[130]. - The company is focused on maintaining compliance with regulatory standards and improving internal controls, as evidenced by the self-evaluation reports presented to the board[158]. Product Development and Innovation - The company’s interferon product line includes the world's first human interferon α2b aerosol spray, which fills a gap in the antiviral field[147]. - The company’s nerve growth factor product, Enjingfu, is designed for nerve injury repair and has significant biological functions for nerve regeneration[148]. - The company has launched two new products in the oncology segment, expected to contribute an additional RMB 200 million in revenue in 2023[96]. - The company has filed 16 patents since its establishment, including 2 national invention patents and 10 utility model patents, enhancing its intellectual property portfolio[178]. - The company has received recognition for its innovative products, including being named a key new product in Tianjin[147]. - The company has received a national invention patent for its "waste gas hydrogen cyanide method" production technology, which is at the world advanced level[186].

证券代码：002581 证券简称：未名医药 山东未名生物医药股份有限公司投资者关系活动记录表 编号：20230512 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 活动类别 | □媒体采访  业绩说明会 □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 网上平台"全景•路演天下"参与未名医药 2022 年度网上业绩说明会 | | | 的广大投资者 | | 时间 | 2023.5.12（15:00-17:00） | | 地点 | "全景•路演天下"（http://rs.p5w.net） | | 上市公司接待 | 董事长岳家霖先生，副总经理刘文俊先生，副总经理徐隽雄先生，独 | | 人员姓名 | 立董事肖杰先生，财务总监刘阳军先生，董事会秘书赵辉先生 | | | Q1：未名天源公司的拆迁补偿协议到底签了没有？补偿资金到 | | | 位没有？ | | | 答：尊敬的投资者，你好！公司将根据相关法律法规和《公司章 | | | 程》的相关规定履行相应审议程序和信息披露义务，请留意公司在指 | | | 定媒体发布的相关公告，谢谢。 | ...

Financial Performance - The company's operating revenue for 2022 was ¥357,080,537.01, a decrease of 11.33% compared to ¥402,713,045.66 in 2021[23]. - The net profit attributable to shareholders was -¥14,689,829.85, representing a decline of 105.42% from ¥271,001,671.69 in the previous year[23]. - The cash flow from operating activities showed a net outflow of -¥54,485,087.46, worsening from -¥46,015,293.51 in 2021, indicating an 18.41% increase in cash outflow[23]. - Basic earnings per share were -¥0.0223, down 105.43% from ¥0.4108 in 2021[23]. - Total assets at the end of 2022 amounted to ¥2,857,915,829.17, reflecting a 3.69% increase from ¥2,756,079,609.10 at the end of 2021[23]. - The net assets attributable to shareholders decreased by 0.62% to ¥2,373,520,735.73 from ¥2,388,210,565.58 in 2021[23]. - The company reported a quarterly operating revenue of ¥87,387,093.61 in Q1, ¥100,257,851.62 in Q2, ¥87,884,145.56 in Q3, and ¥81,551,446.22 in Q4 of 2022[27]. - The net profit attributable to shareholders in Q4 was -¥79,140,215.15, a significant decline compared to previous quarters[28]. - The company experienced a total of -¥6,192,154.14 in non-recurring losses for 2022, contrasting with a gain of ¥15,778,501.14 in 2021[29]. - The company reported a total distributable profit of ¥1,134,738,257.30 for the period, with no cash dividends or stock bonuses proposed[159]. Risk Factors - The company has acknowledged various risks including policy, R&D, safety, environmental, and market competition risks in its future outlook[4]. - The company emphasizes the importance of risk awareness among investors regarding future plans and performance forecasts[4]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its financial performance over the past three years[23]. - The company faces policy risks due to ongoing reforms in the pharmaceutical industry, which may lead to price reductions for some products[94]. - R&D risks are present due to the long and high-risk nature of new drug development, which may affect future profitability[96]. - The company is exposed to safety and environmental risks associated with production processes, necessitating enhanced safety management and compliance[97]. - Increased market competition is anticipated as more companies enter the pharmaceutical sector, prompting the company to enhance its competitive strategies[98]. Corporate Governance - The company strictly adheres to the provisions of the Company Law and Articles of Association regarding board member adjustments, ensuring compliance with relevant requirements[106]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, gradually forming a unique compensation performance assessment system[110]. - The company maintains complete independence from its controlling shareholder in business, personnel, assets, organization, and finance, ensuring autonomous operational capabilities[115]. - The company has implemented a comprehensive information disclosure management system, ensuring accurate, timely, and complete information dissemination to all shareholders[109]. - The company held its annual general meeting with a participation rate of 52.42% and a temporary shareholders' meeting with a participation rate of 34.86%[117]. - The company has developed or revised 28 internal governance regulations during the reporting period, enhancing its governance structure[112]. - The company has a dedicated investor relations management team to handle inquiries and maintain communication with shareholders[109]. - The company has established independent recruitment, training, and performance evaluation systems for its employees, ensuring no interference from the controlling shareholder[116]. - The company has a clear boundary of property rights, owning all necessary assets for its production and operations independently[116]. - The company has committed to a cooperative and win-win approach with stakeholders, balancing the interests of society, shareholders, the company, and employees[111]. Research and Development - R&D expenditure in China's pharmaceutical manufacturing industry increased from RMB 48.847 billion in 2016 to RMB 94.244 billion in 2021, with a compound annual growth rate of 14.05%[34]. - The company operates in five major biopharmaceutical segments, including interferon, nerve growth factor, CRO/CDMO, vaccines, and pharmaceutical intermediates, ensuring stable operations across all segments[37]. - The company completed the clinical phase I trial of recombinant human nerve growth factor eye drops, which showed good systemic safety and tolerance[52]. - The company is focusing on the development of the second-generation product of nerve growth factor, enhancing its competitive edge in the market[48]. - The company has applied for 16 patents, including 2 national invention patents and 10 utility model patents, with 8 utility model patents and 4 software copyrights already protected[46]. - The R&D expenditure for 2022 was 150 million RMB, accounting for 12.5% of total revenue, with plans to increase this to 15% in 2023[138]. Market and Product Development - The biopharmaceutical industry in China is expected to grow significantly, with the market size projected to exceed RMB 4 trillion by 2022, up from RMB 3.57 trillion in 2020, indicating a strong long-term demand for pharmaceuticals[33]. - The company’s vaccine segment includes products such as the inactivated COVID-19 vaccine and the first hepatitis A vaccine prequalified by WHO, showcasing its strong position in vaccine development[42]. - The company’s nerve growth factor product, Enjingfu, is the world's first clinically approved nerve growth factor drug, highlighting its innovation in the field[39]. - The company is currently in the second phase of clinical research for a new eye drop product, which is expected to enhance future revenue and profit growth[68]. - The company is actively seeking opportunities for market expansion and potential mergers or acquisitions to enhance its competitive position[134]. - The company plans to invest 300 million RMB in new technology development over the next two years to improve production efficiency[137]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[137]. Environmental and Social Responsibility - The company strictly adheres to various environmental protection laws and standards, including the "Comprehensive Wastewater Discharge Standards" and "Industrial Enterprise Boundary Noise Emission Standards" during its operations[174]. - The company has established a wastewater treatment workshop that utilizes a multi-step treatment process, ensuring that wastewater meets discharge standards before being released to the municipal sewage treatment plant[178]. - The company has a comprehensive emergency response plan for environmental incidents, which was completed and filed with the relevant authorities in December 2020[180]. - The company actively participated in social responsibility initiatives, donating CNY 76,000 in cash and 38,464 units of medication to support patients with neurological disorders[187]. - The company has paid CNY 4,671.35 in environmental protection tax during the reporting period[182]. - The company did not experience any administrative penalties related to environmental issues during the reporting period[182]. Strategic Initiatives - The company plans to improve its production management system to ensure stable operations and enhance cost-reduction measures through technological advancements[92]. - The company intends to strengthen its product branding and increase market coverage by developing flexible product policies and innovative marketing strategies[93]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[120]. - The company has approved a plan to provide guarantees for its wholly-owned subsidiaries, which may support their operational needs[146]. - The company is actively revising its internal control and audit systems to ensure compliance and improve governance standards[148].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 5、其他非流动资产期末余额比年初余额增加 6579.91%，主要原因系本期预付购置资产所致。 重要内容提示： □适用 不适用 1、应收款项融资余额比年初余额增加 480.78%，主要原因系本期加大回款力度收到银行承兑汇票增加所 致。 公司是否需追溯调整或重述以前年度会计数据 （一）合并资产负债表项目变动的原因说明： 2、其他应收款期末余额比年初余额减少 64.15%，主要原因系本期收回押金所致。 山东未名生物医药股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 山东未名生物医药股份有限公司 2023 年第一季度报告 2 3、持有待售资产期末余额比年初余额减少 96.07%，主要原因系本期出售资产所致。 4、使用权资产期末余额比年初余额减少 98.32%，主要原因系本期偿还完融资租赁借款转固定资产所致。 证券代码：002581 证券简称：未名医药 公告编号：2023-016 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的 ...